H. Biersack

发表

Redifferentiation therapy-induced radioiodine uptake in thyroid cancer.

R. Fimmers, H. Biersack, H. Bender, 1998, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

"High-dose" radioiodine therapy in advanced differentiated thyroid carcinoma.

H. Biersack, H. Bender, H. Palmedo, 1996, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

FDG-PET Findings of Vertebral Compression Fractures in Osteoporosis: Preliminary Results

H. Biersack, H. Palmedo, O. Schmitt, 2002, Osteoporosis International.

Prognostic value of thyroglobulin after thyroidectomy before ablative radioiodine therapy in thyroid cancer.

R. Fimmers, H. Biersack, F. Grünwald, 1996, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

Repeated bone-targeted therapy for hormone-refractory prostate carcinoma: tandomized phase II trial with the new, high-energy radiopharmaceutical rhenium-188 hydroxyethylidenediphosphonate.

R. Fimmers, P. Albers, I. Schmidt-Wolf, 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Rhenium-186 HEDP: palliative radionuclide therapy of painful bone metastases. Preliminary results.

H. Biersack, H. Palmedo, S. Müller, 1997, Scandinavian journal of urology and nephrology.

Ictal and interictal brain SPECT imaging in epilepsy using technetium-99m-ECD.

C E Elger, C. Elger, A. Hufnagel, 1994, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

Pathological Regional Cerebral Blood Flow in Opiate-Dependent Patients during Withdrawal: A HMPAO-SPECT Study

H. Möller, S. Kasper, K. Broich, 1998, Neuropsychobiology.

Intraarterial HCC therapy with I-131-Lipiodol.

W. Caselmann, H. Palmedo, H. Strunk, 2000, Cancer biotherapy & radiopharmaceuticals.

Dose escalation study with rhenium-188 hydroxyethylidene diphosphonate in prostate cancer patients with osseous metastases

H. Biersack, H. Bender, H. Palmedo, 2000, European Journal of Nuclear Medicine.

Immunological consolidation of ovarian carcinoma recurrences with monoclonal anti-idiotype antibody ACA125: immune responses and survival in palliative treatment. See The biology behind: K. A. Foon and M. Bhattacharya-Chatterjee, Are solid tumor anti-idiotype vaccines ready for prime time? Clin. Can

D. Wallwiener, R. Kreienberg, T. Bauknecht, 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.

FDG-PET in monitoring therapy of breast cancer

H. Biersack, H. Bender, H. Palmedo, 2004, European Journal of Nuclear Medicine and Molecular Imaging.

Functional and morphological abnormalities in temporal lobe epilepsy: a comparison of interictal and ictal EEG, CT, MRI, SPECT and PET

W. Heiss, G. Pawlik, W. Burr, 1987, Journal of Neurology.

Scintimammography with technetium-99m methoxyisobutylisonitrile: results of a prospective European multicentre trial

J. Maublant, R. Hustinx, H. Biersack, 1998, European Journal of Nuclear Medicine.

Single photon emission computed tomography imaging of brain tumors.

H. Biersack, F. Grünwald, J. Kropp, 1991, Seminars in nuclear medicine.

Technetium-99m HM-PAO brain SPECT in epileptic patients before and during unilateral hemispheric anesthesia (Wada test): report of three cases.

J Wappenschmidt, M. Kurthen, H. Biersack, 1987, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

Whole-body SPECT/CT for bone scintigraphy: diagnostic value and effect on patient management in oncological patients

H. Schild, Y. Ko, U. Göhring, 2013, European Journal of Nuclear Medicine and Molecular Imaging.

[A comparison of 201Tl and 99mTc-MIBI in the follow-up of differentiated thyroid carcinomas].

A. Bockisch, H. Biersack, F. Grünwald, 1991, Nuklearmedizin. Nuclear medicine.

Can peptide receptor radionuclide therapy be safely applied in florid bone metastases?

H. Biersack, H. Ahmadzadehfar, F. Grünwald, 2012, Nuklearmedizin.

Remission of bone metastases after combined chemotherapy and radionuclide therapy with Re-186 HEDP.

H. Biersack, H. Palmedo, F. Grünwald, 1998, Clinical nuclear medicine.

Positron emission tomography in the clinical staging of patients with Stage I and II testicular germ cell tumors.

P. Albers, H. Biersack, S. C. Mueller, 1999, Urology.

188Re- and 99mTc-MAG3 as prosthetic groups for labeling amines and peptides: approaches with pre- and postconjugate labeling.

H. Biersack, H. Bender, F. Knapp, 1998, Nuclear medicine and biology.

FDG PET and immunoscintigraphy with 99mTc-labeled antibody fragments for detection of the recurrence of colorectal carcinoma.

H. Biersack, H. Bender, F. Grünwald, 2000, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

Comparison of 18FDG-PET with 131iodine and 99mTc-sestamibi scintigraphy in differentiated thyroid cancer.

J. Ruhlmann, H. Biersack, H. Bender, 1997, Thyroid : official journal of the American Thyroid Association.

Possible role of FDG-PET in the early prediction of therapy outcome in liver metastases of colorectal cancer.

H. Biersack, H. Bender, J. Mezger, 1999, Hybridoma.

Introduction of a metabolic joint asymmetry score derived from conventional bone scintigraphy

H. Biersack, S. Ezziddin, A. Sabet, 2015, Nuklearmedizin.